Latest Development Activity News

Rox Resources has reached financial close on A$350 million of debt facilities for the Youanmi Gold Mine, removing the conditions that had stood between the funding package and construction spending. The company has initially drawn A$90.2 million in project debt and used a further A$4 million bank guarantee facility allocation.

Altech Batteries reported a $43.4 million FY2026 loss after abandoning its two major German battery projects, while its CERENERGY subsidiary filed for insolvency and a proposed Malaysian asset sale fell through. The company now faces substantial doubt about its ability to continue as a going concern.

Gold Mountain expanded its Brazilian rare earths portfolio during FY2026, taking Irajuba beyond its original conceptual target and confirming ionic adsorption clay characteristics at Capivara. The progress came alongside an $8.137 million loss, a $4.798 million impairment charge and continued reliance on equity funding.

International Equities Corporation Ltd (ASX:IEQ) returned to a statutory profit in FY2026, but the result was largely supported by discontinued tourism operations while continuing activities remained loss-making. An auditor’s material uncertainty warning and a new secured $1.2 million loan put liquidity at the centre of the investment case.

Vitrafy has added US blood network Versiti to its cryopreservation development programme, with the partnership focused on no-wash platelet preservation and regulatory verification. The deal strengthens the company’s institutional network, but initially generates no revenue and remains subject to US regulatory requirements.

Key Petroleum reduced its FY2026 loss, but the oil and gas explorer continues to rely on equity funding while awaiting Queensland Government decisions on ATP 920 and ATP 924. An auditor’s unmodified opinion still highlights material uncertainty over the company’s ability to continue as a going concern.

Carnarvon Energy has expanded its Bedout prospective resource inventory by 92% and secured a rig for a 2027 exploration campaign, but Dorado remains stalled before FEED and FID. The company ended FY26 with A$97.7 million in cash, no debt and a A$4.2 million after-tax loss.

NGX Limited (ASX:NGX) has warned of a material uncertainty over its ability to continue as a going concern after cash reserves fell to A$1.65 million. The minerals explorer says it will need additional working capital through September 2027, despite advancing graphite, rutile and uranium projects.

EMVision Medical Devices has received a $4.3 million R&D tax refund, adding non-dilutive funding as it progresses clinical work on its emu™ and First Responder devices. The cash arrives against a last reported cash balance of $17.1 million and $4.6 million in remaining grant funding at 30 June 2026.

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Wildcat Resources has secured firm commitments for a A$60 million institutional placement to push Tabba Tabba into engineering, site establishment and construction readiness ahead of a definitive feasibility study targeted for later in 2026. The raise strengthens funding, but part of the share issue still requires shareholder approval and the financing does not establish a final investment decision.

Resonance Health has signed a 24-month alliance with London-based Image Analysis Group, making its quantitative MRI endpoints orderable across IAG’s global clinical-trial network. The opportunity is potentially significant, but remains uncontracted: two pilot studies come first, with no minimum revenue or volume commitments.